Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 214.19M | 228.61M | 306.91M | 369.19M | 583.19M | 614.06M |
Gross Profit | 73.89M | 81.38M | 165.54M | 242.48M | 461.86M | 482.62M |
EBITDA | -77.38M | -74.18M | -50.70M | -100.65M | 14.28M | -12.71M |
Net Income | -87.93M | -82.18M | -59.11M | -105.80M | 7.73M | -18.00M |
Balance Sheet | ||||||
Total Assets | 655.68M | 685.35M | 831.68M | 886.18M | 1.07B | 966.02M |
Cash, Cash Equivalents and Short-Term Investments | 281.79M | 294.22M | 320.66M | 309.36M | 454.13M | 500.93M |
Total Debt | 7.94M | 7.72M | 8.74M | 10.02M | 8.58M | 9.15M |
Total Liabilities | 181.99M | 199.17M | 279.59M | 290.85M | 400.97M | 338.52M |
Stockholders Equity | 473.69M | 486.18M | 552.10M | 595.33M | 667.10M | 627.50M |
Cash Flow | ||||||
Free Cash Flow | -28.13M | -31.02M | 6.35M | -180.69M | ― | -22.00M |
Operating Cash Flow | -30.82M | -31.03M | 6.88M | -180.09M | -66.54M | -21.75M |
Investing Cash Flow | -62.52M | -45.98M | -25.52M | 175.29M | 104.10M | -376.96M |
Financing Cash Flow | -1.14M | -1.44M | 230.00K | -379.00K | -5.07M | -58.91M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $245.34M | 59.10 | 7.41% | ― | 26.86% | ― | |
54 Neutral | $344.96M | ― | -17.22% | ― | -22.93% | -65.68% | |
53 Neutral | $193.43M | 117.49 | 2.17% | ― | 134.52% | ― | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
51 Neutral | $192.25M | ― | -32.97% | ― | ― | ― | |
49 Neutral | $271.46M | ― | 322.49% | ― | -30.66% | 36.48% | |
47 Neutral | $131.29M | ― | -262.12% | ― | 239.92% | 79.41% |
On June 20, 2025, Amarin Corporation entered into a long-term license and supply agreement with Recordati to commercialize VAZKEPA® in 59 European countries. The agreement includes an upfront payment of $25 million, potential milestone payments up to $150 million, and royalties based on net sales. This partnership allows Amarin to streamline its global operations, resulting in approximately $70 million in annual cost savings and an accelerated path to positive cash flow. Additionally, Amarin announced a global restructuring to reduce operating costs, primarily from its European operations, with expected completion by June 30, 2026.
The most recent analyst rating on (AMRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.
At Amarin Corporation’s Annual General Meeting on May 13, 2025, shareholders voted on several proposals, with all but Proposal 12 being approved. Proposal 12, which aimed to allow the Board to allot 10% of the company’s share capital without statutory pre-emption rights, did not receive the necessary shareholder approval despite recommendations from ISS and Glass Lewis. This rejection necessitates the Board to explore alternative compensation arrangements for non-employee directors, potentially impacting the company’s cash position.
The most recent analyst rating on (AMRN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.
On April 29, 2025, Amarin Corporation announced it has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance was achieved following an adjustment in the ratio of its American Depositary Shares to ordinary shares. The company remains committed to maximizing the global value of its primary product, VASCEPA/VAZKEPA, for cardiovascular disease management.
On April 9, 2025, Amarin announced a change in the ratio of its American Depositary Shares (ADS) to ordinary shares, effective April 11, 2025, to maintain its Nasdaq listing. This adjustment, resulting in a one-for-twenty reverse split of ADSs, aims to increase the per-share market price to meet Nasdaq’s minimum bid requirement, although the company cannot guarantee the expected price increase.
On April 4, 2025, Amarin Corporation appointed Michael Torok to its Board of Directors. Torok, co-founder of JEC Capital Partners, brings financial expertise and a focus on maximizing shareholder value. His appointment is expected to strengthen Amarin’s strategic direction and shareholder engagement.